Sermorelin acetate
Geref (sermorelin acetate) is a protein pharmaceutical. Sermorelin acetate was first approved as Geref on 1990-12-28. It is used to treat emaciation and infertility in the USA. The pharmaceutical is active against growth hormone-releasing hormone receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| emaciation | — | D004614 | — |
| infertility | EFO_0000545 | D007246 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H01: Pituitary and hypothalamic hormones and analogues
— H01A: Anterior pituitary lobe hormones and analogues
— H01AC: Somatropin and somatropin agonists
— H01AC04: Sermorelin
V: Various drug classes in atc
— V04: Diagnostic agents
— V04C: Other diagnostic agents in atc
— V04CD: Pituitary function test diagnostic agents
— V04CD03: Sermorelin
HCPCS
Code | Description |
|---|---|
| Level 2: Q0515-Q0515 | Sermorelin Acetate |
| Q0515 | Injection, sermorelin acetate, 1 microgram |
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Autoimmune thyroiditis | D013967 | EFO_0006812 | E06.3 | — | 1 | — | 1 | 1 | 3 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal cell carcinoma | D002292 | 2 | 2 | — | — | — | 2 | ||
| Colorectal neoplasms | D015179 | 1 | 1 | — | — | — | 2 | ||
| Lung neoplasms | D008175 | C34.90 | — | 1 | — | — | — | 1 | |
| Squamous cell carcinoma of head and neck | D000077195 | — | 1 | — | — | — | 1 | ||
| Squamous cell carcinoma | D002294 | — | 1 | — | — | — | 1 | ||
| Xerostomia | D014987 | K11.7 | — | 1 | — | — | — | 1 | |
| Mucositis | D052016 | EFO_1001898 | — | 1 | — | — | — | 1 | |
| Follicular lymphoma | D008224 | C82 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nutritional requirements | D009751 | — | — | — | — | 1 | 1 | ||
| Hashimoto disease | D050031 | EFO_0003779 | E06.3 | — | — | — | — | 1 | 1 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | SERMORELIN ACETATE |
| INN | sermorelin |
| Description | Somatoliberin [Precursor] |
| Classification | Protein |
| Drug class | prehormones or hormone-release stimulating peptides: growth hormone-release stimulating peptides |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 86168-78-7 |
| RxCUI | 56188 |
| ChEMBL ID | CHEMBL1201490 |
| ChEBI ID | — |
| PubChem CID | 16132413 |
| DrugBank | DB00010 |
| UNII ID | 89243S03TE (ChemIDplus, GSRS) |
Target
Agency Approved
GHRHR
GHRHR
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 125 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more